

A COMONOMER, AND A POLYMER STABILIZED WITH IT DURING  
POLYMERIZATION

The present invention relates to an E-vitamin derivative or a compound analogous with it as defined in the preamble of claim 1, to a method for the production of the aforesaid derivative, to its use as defined in claim 16, to a stabilized copolymer as defined in the preamble of claim 17 and to a method for the production of a stabilized copolymer as defined in the preamble of claim 24.

In prior art, specification FI 92212 presents a method for the production of a stable  $\alpha$ -olefin polymer using a Ziegler-Natta type catalyst in which the  $\alpha$ -olefin reacts with a complex comprising a metal of group I-IV of the periodic system and an  $\alpha$ -alkenyl substituted stabilizer co-ordinated to it with a heteroatom as a ligand. The catalyst is attached to a magnesium carrier, and a chain of at least 5 carbons is needed between the stabilizer residue of the stabilizer ligand and the polymerizing functional unsaturated bond.

Further, specification DE 1947590 describes how a component containing a hydrocarbon based, sterically protected hydroxyl group and linked to an  $\alpha$ -vinyl group situated at a distance of at least two carbon atoms is copolymerized in the polymerization conditions of olefins in the presence of an old-generation Ziegler-Natta catalyst. The problem is a low polymerization activity.

A generally known practice is to polymerize polyolefins using Ziegler-Natta type catalysts. The catalyst consists of a metalorganic compound in which the procatalyst is typically an at least partially reduced compound of a transition metal of group IV, V, VI or VII, usually a compound of e.g. titan or zirconium, while the cocatalyst is an organometallic compound of an alkali metal, alkaline earth metal, zinc

or aluminum, e.g. triethylaluminum and diethylmagnesium. An example of such a catalyst is a combination of titan chloride and triethylaluminum. The activity increases considerably when the above-mentioned components are attached to a fixed carrier; e.g.  $\text{MgCl}_2$ . Ziegler-Natta catalysts are characterized by an ability to give the polymer the particle form of the catalyst during polymerization, thus producing polymer particles of 0.2 - 5 mm. The polymer particle thus produced is porous, and without an additive increasing the stability, it is chemically dissolved during use.

A known practice is to use a stabilizer having a large molar mass, e.g. derivatives of tert-butyl phenol and pentaerythritol, as an additive. Another known practice is to use polymer-based and oligomeric molecules. A limitation is, however, a lower solubility in polymer. Substituted phenols and aromatic amines are widely used antioxidants. Usually the polymer product obtained after the polymerization reaction is melted in a so-called extruder stage, and additives improving stability are added to the molten product, whereupon the product is granulated.

Further, the use of so-called metallocene catalysts is known in industry. Such catalysts have been used since the early 1990's in polymerization processes beside or instead of Ziegler-Natta catalysts. Metallocene catalysts are based on a so-called sandwich structure, in which a metallic center, e.g. zirconium, is placed between two cyclopentadienyl rings (bischloro-zirconocene), and on derivatives of that structure. Metallocene catalysts have in some cases increased the polymerization activity even with comonomers that have previously been difficult to copolymerize. Therefore, metallocenes are increasingly used in various industrial applications.

A problem with previously known methods is that the stabilizing additive is added to the product

at the extruder stage, which is why it has not been possible to utilize a catalyst producing a particle product and a polymerization process because of the stability problem.

5           A further problem is that the additives in the polymer product vanish during use. One of the reasons for this is that the additives improving stability drift to the surface of the product, with the result that the stabilizing effect is diminished and  
10 disappears with time and that the additives may get into contact e.g. with foodstuffs. In addition, it has been established that some additives have estrogenic effects. The loss of additives in the product may also be partly due to evaporation taking place during processing or dissolution occurring during washing.  
15


          Another problem is irregular distribution of additives in the polymer product. Irregular distribution may result e.g. from an incompatibility of the stabilizers with paraffin-type hydrocarbon-based polymers due to a high polarity. In addition, the amount of stabilizer added to polyolefins has to be limited because of the tendency of the stabilizers to crystallize.  
20

          Further problems are a poor product yield and an atacticity of the product in polymerization carried out using a Ziegler-Natta catalyst.  
25


          The object of the invention is to eliminate the problems referred to above and to disclose a new usable comonomer having a stabilizing effect. A further object of the invention is to disclose a copolymer stabilized during polymerization.  
30

          The E-vitamin derivative or the compound analogous with it, its production method and the stabilized copolymer and its production method according to the invention are characterized by what is presented in the claims.  
35

The E-vitamin derivative of the invention or the compound analogous with it, i.e. a compound having a corresponding structure, has the following formula (I):



15 where X is an oxygen or sulfur atom, p is an integer = 0 or 1, and R<sub>3</sub> - R<sub>11</sub> are identical or different groups selected from hydrogen, C<sub>1-6</sub>alkyl or α-alkene having the formula (II)




where n, m and o are integers 0 - 4 independent of each other and R<sub>1</sub> and R<sub>2</sub> are identical or different groups selected from hydrogen or C<sub>1-6</sub>alkyl or C<sub>1-6</sub>alkene, which may be substituted with an aromatic ring, e.g. a styrene derivative

or R<sub>7</sub> and R<sub>8</sub> are together an oxygen atom and/or R<sub>4</sub> and R<sub>5</sub> and/or R<sub>10</sub> and R<sub>11</sub> form together with the carbon atoms to which they are bonded a benzene ring, which may be substituted with groups selected from hydrogen, C<sub>1-6</sub>alkyl or α-alkene.

C<sub>1-6</sub>alkyl or C<sub>1-6</sub>alkene means a branched or non-branched hydrocarbon chain containing 1 - 6 carbon atoms.


35 In an embodiment of the invention, the derivative has the formula (III)

5



(III)


or the formula (IV)



(IV)

where X is an oxygen or sulfur atom and  $R_3 - R_{11}$  are identical or different groups selected from hydrogen,  $C_{1-6}$ alkyl or  $\alpha$ -alkene having the formula (II).

In an embodiment of the invention, the derivative has the formula (V)



(V)

where  $R_3 - R_{11}$  are identical or different groups selected from hydrogen,  $C_{1-6}$ alkyl or  $\alpha$ -alkene having the formula (II),

or  $R_7$  and  $R_8$  are together an oxygen atom and/or  $R_4$  and  $R_5$  and/or  $R_{10}$  and  $R_{11}$  form together with the carbon atoms to which they are bonded a benzene

ring, which may be substituted with groups selected from hydrogen, C<sub>1-6</sub>alkyl or  $\alpha$ -alkene.

The E-vitamin derivative of the invention or the compound analogous with it preferably has a structure containing at least one fused benzene ring and a ring containing a heteroatom, and an  $\alpha$ -chain linked with them. The heteroatom, such as an oxygen or sulfur atom, and the hydroxy group are preferably bonded to opposite sides of the benzene ring of the heterocycle, with the result that an effect stabilizing the compound is produced.

One group of E-vitamin derivatives according to the invention is formed by compounds consistent with formula (III) or (IV), where one the 2-position groups R<sub>3</sub> and R<sub>4</sub> or 3-position groups R<sub>5</sub> and R<sub>6</sub> is hydrogen or C<sub>1-6</sub>alkyl and the other an  $\alpha$ -alkene consistent with formula (II), R<sub>7</sub> - R<sub>11</sub> are hydrogens or C<sub>1-6</sub>alkyls and the sum of integers m, n and o is 1 - 12 and R<sub>1</sub> and R<sub>2</sub> are as specified above.

A preferred group of compounds according to the invention are compounds (III) or (IV) in which one of the heterocycle 2-position groups R<sub>3</sub> and R<sub>4</sub> or of the heterocycle 3-position groups R<sub>5</sub> and R<sub>6</sub> is a hydrogen or C<sub>1-6</sub>alkyl while the other is an  $\alpha$ -alkene consistent with formula (II), where n + m + o is an integer 1 - 6 and R<sub>1</sub> and R<sub>2</sub> are hydrogens and R<sub>9</sub> - R<sub>11</sub> are C<sub>1-6</sub>alkyls. In an embodiment, the derivative is a compound consistent with formula (III), where X is oxygen, one of groups R<sub>3</sub> and R<sub>4</sub> is a methyl group and the other is an  $\alpha$ -alkene consistent with formula (II), where n + m + o equals 1 or 2 and R<sub>1</sub> and R<sub>2</sub> are hydrogens, R<sub>5</sub> - R<sub>8</sub> are hydrogens and R<sub>9</sub> - R<sub>11</sub> are methyls. R<sub>3</sub> or R<sub>4</sub> may alternatively be a hydrogen instead of a methyl group. In an embodiment, the derivative is a compound consistent with formula (IV), where X is oxygen, R<sub>1</sub> - R<sub>4</sub> are hydrogens, one of groups R<sub>5</sub> and R<sub>6</sub> is



an  $\alpha$ -alkene consistent with formula (II), where  $n + m + o$  equals 4, and  $R_9 - R_{11}$  are methyl groups.


Another group of E-vitamin derivatives according to the invention consists of compounds consistent with formula (III) or (IV) where one of groups  $R_9 - R_{11}$  in 5, 7 and 8-position (formula III) or 4, 6 and 7-position (formula IV) in the heterocycle is an  $\alpha$ -alkene consistent with formula (II) and two of the groups are hydrogens or  $C_{1-6}$ alkyls, and the sum of the integers  $m$ ,  $n$  and  $o$  is in the range of 1 - 12 and  $R_1$  and  $R_2$  are as specified above.

A preferred group of compounds according to the invention consists of compounds (III) or (IV) in which  $R_9$  in 5-position (formula III) or 4-position in the heterocycle is an  $\alpha$ -alkene consistent with formula (II) where the integer  $n$  is 0 or 1,  $m$  is 0 or 1 and  $o$  is 1 - 4 and  $R_1$  and  $R_2$  are hydrogens or  $C_{1-6}$ alkyls.  $R_{10}$  and  $R_{11}$  are hydrogens or  $C_{1-6}$ alkyls. In a preferred case, in a derivative consistent with formula (III),  $X$  is oxygen,  $R_1 - R_4$  and  $R_{10} - R_{11}$  are methyls,  $R_5 - R_8$  are hydrogens and  $R_9$  is an  $\alpha$ -alkene consistent with formula (II) where  $n$  is 0,  $m$  is 1 and  $o$  is 3. In an embodiment, the derivative is a compound consistent with formula (III) where  $X$  is oxygen,  $R_3 - R_4$  and  $R_{10} - R_{11}$  are methyl groups,  $R_5 - R_8$  are hydrogens and  $R_9$  is an  $\alpha$ -alkene consistent with formula (II) where  $m$  is 0 and  $n + o$  is 1.

E-vitamin derivatives consistent with formula (III) include e.g. 6-hydroxy-2,5,7,8-tetramethyl-2-(but-3-enyl)-chromane, 6-hydroxy-2,5,7,8-tetramethyl-2-(prop-2-enyl)-chromane, 6-hydroxy-2,2,7,8-tetramethyl-5-(1,1-dimethyl-hex-5-enyl)-chromane and 6-hydroxy-2,2,7,8-tetramethyl-5-(prop-2-enyl)-chromane. E-vitamin derivatives consistent with formula (IV) include e.g. 5-hydroxy-4,6,7-trimethyl-3-(hex-5-enyl)-benzofurane.

In an embodiment of the invention, the compound analogous with the E-vitamin derivative is a compound consistent with formula (IV) in which one of groups  $R_9 - R_{11}$  is an  $\alpha$ -alkene consistent with formula (II) and the other groups are hydrogens or  $C_{1-6}$ alkyls and  $R_3 - R_8$  are hydrogens or  $C_{1-6}$ alkyls. Alternatively,  $R_7$  and  $R_8$  are together an oxygen atom and/or  $R_4$  and  $R_5$ , together with the carbon atoms to which they are bonded, form a benzene ring. In a preferred embodiment,  $R_{10}$  is an  $\alpha$ -alkene consistent with formula (II) where  $n$  is 0 or 1,  $m$  is 0 or 1 and  $o$  is an integer 1 - 4 and  $R_1$  and  $R_2$  are methyl groups,  $R_9$  is a  $C_{1-6}$ alkyl,  $R_{11}$  is a hydrogen,  $R_7$  and  $R_8$  are together an oxygen atom and  $R_4$  and  $R_5$ , together with the carbon atoms to which they are bonded, form a benzene ring. A compound consistent with formula (V) may be e.g. a thioxanthone derivative, such as a hydroxythioxanthone derivative.

The derivative according to the invention may naturally have any kind of structure corresponding to those described above, e.g.



An E-vitamin derivative consistent with formula (I) or a compound analogous with it is produced using suitable synthesizing methods of organic chemistry.



The E-vitamin derivative of the invention or the compound (I) analogous with it can be produced e.g.

5 A) by allowing a hydroquinone derivative to react with a suitable tertiary unsaturated alcohol or thiol.

In method A), a compound consistent with formula (I) can be produced directly by allowing a hydroquinone derivative, such as a mono-, di- or trialkylhydroquinone, e.g. dimethyl or trimethyl hydroquinone, 10 to react with a suitable unsaturated alcohol, such as alka-dienol, e.g. 2,7-octadien-1-ol or 3-methyl-1,6-heptadien-3-ol, or thiol in a suitable solvent. Optionally, according to method A), in a first stage it is possible to prepare an intermediate product containing a (halogen-alkyl) group or a corresponding 15 group by allowing a hydroquinone derivative to react with a suitable unsaturated alcohol, such as 2-alkyl-alka-1,x-dien-3-ol, e.g. 3-methylhept-1,6-dien-3-ol or 3-alkyl-x-halogen-alk-1-en-3-ol, e.g. 3-methyl-5-chlor-pent-1-en-3-ol, or thiol in the presence of a 20 suitable catalyst in a suitable solvent. In a second stage, a compound consistent with formula (I) is prepared by splitting off a hydrogen halogenide or a corresponding compound from the halogen alkyl group or an equivalent group in the intermediate product in the 25 presence of an alkali. A suitable catalyst is e.g. a metal halide, such as aluminum chloride and zinc chloride. Suitable solvents are e.g. acids, such as formic acid, sulfuric acid or equivalent, tetrahydrofurane (THF) and dichloromethane. A suitable alkali is e.g. 30 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU).

An E-vitamin derivative or a compound (I) analogous with it as provided by the invention can be produced e.g.

35 B) by allowing a hydroquinone derivative to react with a suitable unsaturated alcohol or thiol and

adding an  $\alpha$ -alkene to the fused heterocyclic derivative thus formed.

In a first step in method B), a fused heterocyclic derivative can be produced by allowing a hydroquinone derivative, such as mono-, di- or trialkylhydroquinone, to react with a suitable tertiary unsaturated alcohol, such as 3-alkyl-alk-1-en-3-ol e.g. 3-methyl-but-1-en-3-ol or thiol, in the presence of a suitable catalyst in a suitable solvent. A suitable catalyst is e.g. a metallic halide, such as aluminum chloride and zinc chloride. Suitable solvents are e.g. tetrahydrofuran (THF) and dichloromethane and acids, e.g. formic acid. In a second step in the method, an  $\alpha$ -alkene consistent with formula (II) is added to the heterocyclic derivative in acid conditions.

The E-vitamin derivative of the invention or a compound analogous with it is preferably used as a stabilizing comonomer, i.e. as a stabilizer, in copolymerization to produce a stabilized copolymer. The function of the stabilizer is to prevent and reduce the harmful effects of heat, UV radiation, oxygen and/or ozone on the copolymer.

The stabilized copolymer consists of at least one monomer variety and a stabilizing comonomer. The monomer in question is an olefin and/or a cyclic and/or aromatic compound containing an  $\alpha$ -alkene chain. The olefin monomer may be e.g. ethylene, propylene, 1-butene, isobutene and/or 4-methyl-1-pentene or the like or a mixture of these. The aromatic compound may be styrene. Naturally, the monomer may be of any type. The stabilizing comonomer is an E-vitamin derivative or a compound analogous with it which has the formula (I) and which has a clearly stabilizing effect and which can be polymerized under normal polymerization conditions. The stabilizing comonomer may be e.g. a derivative of chromane-, benzofurane- or hydroxythioxanthone.

The comonomer, i.e. stabilizer of the invention, is preferably bonded by its  $\alpha$ -alkene chain to a copolymer.

5 In an embodiment of the invention, the copolymer comprises one olefin or styrene monomer variety and an E-vitamin derivative according to the invention or a compound analogous with it having the formula (III), (IV) or (V).

10 The copolymer preferably belongs to so-called addition polymers. When an addition polymer is formed, no small-molecule side products are generated, i.e. the structural unit of the polymer has a monomeric composition. Monomers may have a linear or a branched hydrocarbon chain, and they contain at least one dual  
15 bond enabling a polymerization reaction to take place.

In the copolymer, different monomer varieties may be arranged in different ways, e.g. in a regular fashion, such as alternately, as a segment or in other ways like this. The monomers may also be arranged in  
20 an irregular fashion. The structure of the copolymer is preferably mainly regular, such as isotactic or syndiotactic, as is typically the case when monomers are polymerized using metallocene or Ziegler-Natta catalysts (stereospecific polymerization). A feature  
25 characteristic of especially products obtained via polymerization using metallocene catalysts is a syndiotactic form. The crystallizing properties of the polymer depend on the regularity of the structure, among other things. However, the polymer may also contain  
30 atactic parts or it may completely atactic.

In the method of the invention for the production of a stabilized copolymer, at least one monomer variety and a stabilizing comonomer are copolymerized in the presence of a catalyst in a single-stage  
35 or multi-stage polymerization process known in itself, using e.g. precipitation, solution or gas phase polymerization, which will not be described here in detail.

According to an embodiment, the catalyst used in copolymerization is preferably e.g. a liquid or solid metallocene catalyst or its derivative known in itself, which is formed from derivatives of transition metals, including lanthanides. Among the best transition metals for the production of catalysts are transition metals belonging to groups 3 and 4, and lanthanides whose oxidation number is +2, +3 or +4. The metallocene components contain 1 - 3 anionic or neutral groups having a  $\pi$ -bond. To improve the activity of the catalyst, a cocatalyst, which often consists of methylalumoxane (MAO), is generally used. More preferably, MAO can be replaced e.g. with compounds containing boron, e.g. tri(hydrocarbyl)boron and its halogenated derivatives. The cocatalyst used may be e.g. tetraphenyl borate. In the copolymerization method of the invention, it is possible to use e.g. a metallocene catalyst of the type described in patent application FI 941662. Naturally, in the copolymerization method in question, it is also possible to use other catalysts used in this field. The catalyst may comprise a solid carrier. The carrier may consist of any carrier material, which will not be described here in detail.

In an embodiment of the invention, the catalyst used in copolymerization contains a  $\pi$ -cyclopentadienyl transition metal compound and an alumoxane compound. In an alternative embodiment, the catalyst contains a  $\pi$ -cyclopentadienyl transition metal compound and a compound containing boron.

In an embodiment, the stabilizing comonomer is chemically complexed e.g. by its heteroatom to the catalyst, being bound via a chemical bond e.g. to a Zr atom of the catalyst. The comonomer may naturally also be used as such or mixed with other monomers e.g. in the polymerization solution during polymerization.

At the polymerization stage, the stabilizing comonomer and the monomers, e.g. olefin and/or styrene monomers, are copolymerized, in which process the comonomer of the invention is polymerized substantially  
5 along with other monomers, being simultaneously chemically bound to the copolymer. The monomer to be polymerized is bound to an active point, e.g. a Zr atom in the catalyst, causing faster polymerization. The polymer grows as the structural units of the copolymer are  
10 increasing. The copolymer contains different monomers in certain proportions.

The copolymer may be e.g. an ethylene/-, propylene/-, butylene/- or styrene/E-vitamin derivative-copolymer. The copolymerization product may naturally  
15 consist of more than two monomer varieties. Using different production methods and proportions of different monomers, it is possible to adjust the properties of the copolymer.

Copolymers as provided by the invention can  
20 be used either as such or in a mixture with other polymers. A copolymer stabilized with a comonomer according to the invention can be used e.g. as packing material in the foodstuff industry.

The E-vitamin derivative of the invention or  
25 the compound analogous with it has the advantage that it is able to polymerize in typical polymerization conditions with a good yield and that it has a good ability to inhibit oxidation, allowing it to be used as an oxidation inhibitor in polymer production. Fur-  
30 thermore, the comonomer improves the adhesion properties of polymers e.g. with respect to fillers.

The copolymer of the invention has the advantage that the stabilizing comonomer, i.e. stabilizer, is chemically bonded to the polymer structure during  
35 polymerization, which means that it is uniformly distributed in the entire polymer and the chemical bonds prevent the loss of stabilizer in the product, in

other words, they prevent the stabilizer from drifting toward the surface of the product during use. Thus, the stabilizer will not drift e.g. to a foodstuff protected with plastic and is therefore not transferred to people.

The copolymerization method of the invention has the advantage that it allows the use of a metallocene catalyst. In polymerization conditions, such a catalyst works better than other catalysts known at present. When the metallocene catalyst in question is used, a polymer product having a syndiotactic structure and therefore a higher melting point can be manufactured.

A further advantage provided by copolymerization according to the invention is that stabilization is performed during polymerization, in other words, the stabilizer is added as a comonomer to the polymerization product essentially during polymerization, so that the product is directly ready for further processing, in other words, the product thus obtained need not be melted again and fed into an extruder. Thus, a saving is also made in the investment costs of the extruder, which may amount to several tens of millions, even over a hundred million FIM.

In the following, the invention will be described by the aid of a detailed examples of its embodiments with reference to the drawings, wherein

Fig. 1 presents the results of a mass spectrometry analysis of a comonomer according to the invention, 5-hydroxy-4,6,7-trimethyl-3-(hex-5-enyl)-benzofurane,

Fig. 2 presents the results of an NMR-spectrometry analysis of a comonomer according to the invention, 5-hydroxy-4,6,7-trimethyl-3-(hex-5-enyl)-benzofurane,


Fig. 3 presents the results of a mass spectrometry analysis of a comonomer according to the in-



vention, 6-hydroxy-2,5,7,8-tetramethyl-2-(but-3-enyl)-chromane, and

Fig. 4 presents the results of an NMR-spectrometry analysis of a comonomer according to the invention, 6-hydroxy-2,5,7,8-tetramethyl-2-(but-3-enyl)-chromane.

Example 1; preparation of 6-hydroxy-2,5,7,8-tetramethyl-2-(but-3-enyl)-chromane.



Preparation of 3-methylhept-1,6-dien-3-ol:

To 232 g (0.4 mol) of vinyl magnesium chloride in THF was added a solution consisting of 35 g (0.36 mol) of 5-hexene-2-one in 150 ml of anhydrous THF. The reaction mixture was stirred for 20 h at room temperature, whereupon it was cautiously poured into 450 ml of cold, saturated, aqueous  $\text{NH}_4\text{Cl}$  solution. The organic extract was concentrated and diffused with dichloromethane, dried using  $\text{Na}_2\text{SO}_4$  and concentrated. The residue was distilled, and the yield obtained was 35.5 g (78%) 3-methylhept-1,6-dien-3-ol; t.p.  $45^\circ\text{C}/10\text{ mmHg}$ .



Preparation of 6-hydroxy-2,5,7,8-tetramethyl-2-(4-chloro-butyl)-chromane:


A suspension containing 20 g (0.150 mol) anhydrous  $\text{AlCl}_3$  in 200 ml of dichloromethane was stirred at 0 °C while at the same time adding 25.8 g (0.42 mol) of  $\text{CH}_3\text{NO}_2$  under a protective layer of argon. After the mixture had been stirred for 10 min at 0°C, 30.4 g (0.2 mol) of trimethyl-hydroquinone was added in batches. The brown suspension obtained as a result was cooled to -20 °C and a solution consisting of 3-methylhept-1,6-dien-3-ol in 750 ml of dichloromethane was added drop by drop during 0.5 h. The mixture thus produced was allowed to cool down slowly to room temperature, and it was stirred overnight, whereupon it was poured on ice/water. The organic layer was collected, washed twice using a  $\text{NaHCO}_3$  solution and concentrated. The yield thus obtained was 40 g of a raw product containing insignificant impurities. The raw product was distilled, and the yield thus produced was 15 g (25 %) of 6-hydroxy-2,5,7,8-tetramethyl-2-(4-chlorobutyl)-chromane fraction in the form of a light brown liquid, t.p. 180 °C/1 mmHg, which was crystallized overnight in a cooler mp X °C.  $^1\text{H}$  NMR: 1.22 (s, 3H,  $\text{CH}_3\text{-C}(2)$ ); 1.5(d, 3H,  $\text{-CHClCH}_3$ ) 1.65 (m, 2H,  $\text{ArCH}_2\text{-CH}_2\text{-}$ ) 1.8 (m, 4H,  $\text{-CH}_2\text{-CH}_2\text{-}$ ) 2.1, 2.12, 2.15 (3s, 9H,  $\text{ArCH}_3$ ); 2.62 (t, 2H,  $\text{CH}_2\text{Ar}$ ); 4.1 (m, 1H, CH) and 4.23 (s, 1H, OH).  $^{13}\text{C}$  NMR: 11.3, 11.8, 12.2, 20.7, 23.6, 25.2, 31.3, 34.4, 36.7, 59.1, 73.9, 117.1, 118.5, 121.1, 122.5, 144.7 and 145.2.

Preparation of 6-hydroxy-2,5,7,8-tetramethyl-2-(but-3-enyl)-chromane:

To 14.8 g (0.05 mol) of 6-hydroxy-2,5,7,8-tetramethyl-2-(4-chlorobutyl)-chromane was added 36.3 g (0.24 mol) of 1,8-diazabicyclo(5.4.0)undec-7-ene (DBU) and the solution was heated to 120 °C and stirred for 20 h. After that, the reaction mixture was

allowed to cool down to room temperature, poured into 350 ml of dichloromethane and washed repeatedly using diluted HCl. The organic layer was concentrated, and the yield thus obtained was 10.2 g of raw product that was free of DBU. In addition, the material was purified by distilling, and the result thus obtained was 5g (38 %) of 6-hydroxy-2,5,7,8-tetramethyl-2-(but-3-enyl)-chromane; t.p. 154 °C/1mmHg.


10 Example 2; preparation of 5-hydroxy-4,6,7-trimethyl-3-(hex-5-enyl)-benzofurane:



25 Trimethyl hydroquinone (23.7 g) and 2,7-octadien-1-ol (19.7 g) were weighed and put into a reaction vessel and 50 ml of formic acid was added into the mixture. The temperature of the mixture was raised to the boiling point of formic acid, and the reaction was allowed to continue for three hours. The reaction mixture was poured into 150 ml of ice-water mixture, and the organic phase was recovered in diethyl ether. The organic solvent was evaporated, whereupon 100 ml of methanol and 1 ml of hydrochloric acid was added to the residue. The reaction mixture was hydrolyzed at the boiling point of methanol for 30 min, whereupon the solvent was evaporated from the mixture. The mix-

ture was dissolved in diethyl ether, and the organic phase was washed twice using sodium hydrogen carbonate and five times using distilled water. The diethyl ether was evaporated. At this point, the yield was 5 48.0 g. n-hexane was added to the mixture, which was then stirred for 30 min at the boiling point of hexane, whereupon the mixture was allowed to cool down to room temperature. The portion not dissolved in hexane, mainly consisting of inert trimethyl hydroquinone and 10 the product, was separated from the mixture by filtering. The solid portion was dissolved in a small amount of ethanol and precipitated by adding some water into the solution, whereupon the product (7.5 g) was separated by filtering. After that, based on mass spec- 15 trometry (Fig. 1) and NMR spectrometry (Fig. 2) analyses, the product was identified as 5-hydroxy-4,6,7-trimethyl-3-(hex-5-enyl)-benzofurane.

Example 3; preparation of 6-hydroxy-2,2,7,8-tetramethyl-5-(1,1-dimethyl-hex-5-enyl)-chromane 20




Dimethyl hydroquinone and formic acid were mixed together, and 3-methylbuten-3-ol was added little by little into the reaction mixture during one

hour. The mixture was allowed to react for 2 h at the boiling point of formic acid, whereupon the reaction was interrupted by adding some ice-water mixture into it. The organic phase was recovered in diethyl ether and washed several times with water. The organic phase was evaporated, and 75 ml of methanol and 1 ml of concentrated hydrochloric acid was added into the residue, whereupon the mixture has hydrolyzed for half an hour at the boiling point of methanol. The methanol was evaporated, and the residue was dissolved in diethyl ether, which was washed alternately twice with sodium hydrogen carbonate and five times with water. The diethyl ether was evaporated and the residue was distilled in a vacuum. The intermediate product (1.25 g), 6-hydroxy-2,2,7,8-tetramethyl-chromane, was recovered in conditions as follows:  $p = 0.2$  mbar and  $T = 110 - 120$  °C.

6-hydroxy-2,2,7,8-tetramethylchromane and 7-methyl-1,6-octadiene were mixed together. The reaction solution was heated, whereupon an acid catalyzer was added into it. The mixture was allowed to react during 24 hours, and the product, 6-hydroxy-2,2,7,8-tetramethyl-5-(1,1-dimethyl-hex-5-enyl)-chromane, was separated by the conventional method and purified by distilling.

Example 4; preparation of 6-hydroxy-2,5,7,8-tetramethyl-2-(but-3-enyl)-chromane




15 1.02 g of trimethyl hydroquinone, 0.844 g of 3-hydroxy-3-methyl-1,6-heptadiene and 10 ml of formic acid (98 %) were added into a 50-ml reaction vessel. The temperature was increased to the boiling point of formic acid, at which temperature the reaction was allowed to continue for 2 h 50 min. The reaction was interrupted by pouring the mixture into an ice-water mixture, whereupon the organic phase was recovered and washed in the conventional manner. From the product were first separated the portions not dissolved in hexane, whereupon the product was dissolved in ethanol, precipitated with water and washed using hexane and diethyl ether. The yield was 1.3 g. The product was identified via mass spectrometry (Fig. 3) and NMR spectrometry (Fig. 4) analyses as 6-hydroxy-2,5,7,8-tetramethyl-2-(but-3-enyl)-chromane.

20

25

30

Example 5; preparation of 6-hydroxy-2,2,7,8-tetramethyl-5-(prop-2-enyl)-chromane




Dimethyl hydroquinone and formic acid were mixed together, and 3-methylbuten-3-ol was added little by little into the reaction mixture during one hour. The mixture was allowed to react for 2 h at the boiling point of formic acid, whereupon the reaction was interrupted by adding some ice-water mixture into the mixture. The organic phase was recovered in diethyl ether and washed several times with water. The organic phase was evaporated and 75 ml of methanol and 1 ml of concentrated hydrochloric acid was added into the residue, whereupon the mixture was hydrolyzed for half an hour at the boiling point of methanol. The methanol was evaporated, and the residue was dissolved in diethyl ether, which was washed alternately twice with sodium hydrogen carbonate and five times with water. The diethyl ether was evaporated, and the residue was distilled in vacuum. The intermediate product

(1.25 g), 6-hydroxy-2,2,7,8-tetramethyl-chromane, was recovered under the following conditions:  $p = 0.2$  mbar and  $T = 110 - 120$  °C.

The intermediate product (0.5 g) was dissolved in 10 ml of acetone.  $K_2CO_3$  (0.37 g) was added gradually and the mixture was stirred for 30 min, whereupon  $C_3H_5Br$  (0.33 g) was added gradually. A reflux condenser was used during the reaction. The final product, 6-hydroxy-2,2,7,8-tetramethyl-5-(prop-2-enyl)-chromane, was obtained by heating the mixture for 48 h. The product was separated from the mixture via column chromatography.

#### Example 6; Preparation of hydroxythioxanthone



A hydroxythioxanthone derivative was prepared from 6-tert-butyl-(2-(1,1-dimethylhept-6-enyl))-phenol, which can be produced e.g. by a method according to patent PCT/FI95/00196, and from thiosalicylic acid in a manner known in itself.

35

#### Example 7; copolymerization



A polymerization test was carried out to experiment on copolymerization of 6-hydroxy-2,5,7,8-tetramethyl-2-(but-3-enyl)-chromane and propylene in the presence of a metallocene catalyst. The metallocene catalyst consisted of  $\pi$ -cyclo-pentadienyl transition metal and alumoxane.

The treatment of the  $\pi$ -cyclo-pentadienyl transition metal and alumoxane as well as the comonomer was performed in a nitrogen cabinet containing under 2 ppm oxygen and under 5 ppm water. The polymerization was carried out in an autoclave equipped with a turbine mixer. The reaction temperature was adjusted with an accuracy of 0.3 °C.

The dry autoclave was evacuated and rinsed with water. This was repeated three times. A first batch of distilled toluene was fed into the reactor by using nitrogen over-pressure. 5 mg of ansa metallocene catalyst was dissolved in a second batch of MAO/toluene solution and pre-activated by letting them interact with each other at room temperature for 5 min.

The catalyst/activator mixture was fed into the reactor. Pre-polymerization was started by adding a propylene monomer. After 3 min., a comonomer diluted with toluene was added using propylene gas, until the partial pressure of propylene reached 2 bar. The polymerization activity was monitored by measuring the propylene consumption while maintaining a constant total pressure in the reactor by continuously adding gaseous propylene. After 30 min, polymerization was interrupted by stopping the supply of propylene and adding 100 ml of methanol. Polyolefin was filtered and the catalyst residue was removed by treating the product, i.e. the copolymer, with a 1-% methanol/HCl solution. The product was washed twice with ethanol, dried in vacuum at a temperature of 50 °C and weighed. The amount of copolymer obtained was 3 g. The copolymer

was diffused using a Soxhlet device before determining the concentration of bonded stabilizer. The results of the polymerization this means that are presented in Table 1.

5 Table 1 shows that the OIT temperature rises as the comonomer content increases, which is an indication of the effect of the stabilizer. Further, it can be seen from Table 1 that crystallization of the product decreases at higher copolymer content levels,  
10 indicating that the comonomer is chemically bonded to the rest of the polymer.

Table 1. The results of copolymerization of 6-hydroxy-2,5,7,8-tetramethyl-2-(but-3-enyl)-chromane  
15 and propylene.

| Test | Stabilizer | Zr<br>$\mu\text{mol/l}$ | Al<br>$\text{mmol/l}$ | Stab<br>/Zr<br>Mol/<br>Mol | Stab/<br>Al<br>Mol/<br>mol | T <sub>M</sub><br>°C | Crys<br>% | Product<br>kg/mol<br>Zr h<br>atm | OIT |
|------|------------|-------------------------|-----------------------|----------------------------|----------------------------|----------------------|-----------|----------------------------------|-----|
| 1    | -          | 42                      | 126                   | -                          | -                          | 128.4                | 73.4      | 5644                             | 210 |
| 2    | +          | 44                      | 132                   | 120                        | 0.040                      | 129.1                | 69.7      | 3984                             | 229 |
| 3    | +          | 44                      | 132                   | 120                        | 0.040                      | 131.0                | 64.6      | 3590                             | 230 |
| 4    | +          | 44                      | 132                   | 265                        | 0.086                      | 127.2                | 56.0      | 2510                             | 244 |
| 5    | +          | 44                      | 132                   | 356                        | 0.120                      | 129.0                | 58.2      | 2943                             | 248 |

The E-vitamin derivative of the invention or  
20 the compound analogous with it is suited for use in different applications, e.g. for the manufacture of any kind of copolymer. Moreover, the copolymer of the invention is suited for use as different applications for any purpose.

25 The embodiments of the invention are not restricted to the examples presented above; instead, they may be varied in the scope of the following claims.